荣昌生物（09995.HK）今日盘中大涨5.03%，引发市场关注。
消息面上，荣昌生物于10月15日宣布，其自主研发的全球首创BLyS/APRIL双靶点融合蛋白创新药泰它西普（商品名：泰爱®）用于治疗原发性免疫球蛋白A（IgA）肾病的上市申请，已获国家药品监督管理局药品审评中心（CDE）受理，并纳入优先审评程序。这使得泰它西普成为IgA肾病领域首个申报上市的国产原研新药。
值得注意的是，此次申报的剂型为泰它西普注射液（预充式注射器装），这将为患者提供更加便捷的给药方式。这一重大进展表明荣昌生物在创新药研发领域的实力，也为公司未来在IgA肾病治疗市场的布局奠定了坚实基础，因此引发了投资者的积极反应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.